Clinical Trial Update: Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating venetoclax or placebo with reduced-intensity conditioning hematopoietic cell transplant followed by maintenance therapy for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: NOT_YET_RECRUITING